Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-23T06:28:16.792Z Has data issue: false hasContentIssue false

Introduction: Amyloid-Based Interventions in Alzheimer's Disease

Published online by Cambridge University Press:  07 November 2014

Abstract

We appear to be on the brink of a new epoch of treatment for Alzheimer's disease. Compelling evidence suggests that Aβ secretion is the triggering event in the pathogenesis of Alzheimer's disease, and that tau aggregation may be an important secondary event linked to neurodegeneration. Prophylactic administration of anti-amyloid agents designed to prevent Aβ accumulation in persons with subclinical disease is likely to be more effective than therapeutic interventions in established Alzheimer's disease. Drug development programs in Alzheimer's disease focus primarily on agents with anti-amyloid disease-modifying properties, and many different pharmacologic approaches to reducing amyloid pathology and tauopathy are being studied. Classes of therapeutic modalities currently in advanced-stage clinical trial testing include forms of immunotherapy (active β-amyloid immunoconjugate and human intravenous immunoglobulin), a γ-secretase inhibitor, the selective Aβ42-lowering agent R-flurbiprofen, and the anti-aggregation agent tramiprosate. Non-traditional dementia therapies such as the HMG-CoA reductase inhibitors (statins), valproate, and lithium are now being assessed for clinical benefit as anti-amyloid disease-modifying treatments. Positive findings of efficacy and safety from clinical studies are necessary but not sufficient to demonstrate that a drug has disease-modifying properties. Definitive proof of disease-modification requires evidence from validated animal models of Alzheimer's disease; rigorously controlled clinical trials showing a significantly improved, stabilized, or slowed rate of decline in cognitive and global function compared to placebo; and prospectively obtained evidence from surrogate biomarkers that the treatment resulted in measurable biological changes associated with the underlying disease process.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Hebert, LE, Scherr, PA, Scherr, JL, Bienias, JL, Bennett, DA, Evans, DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:11191122.CrossRefGoogle ScholarPubMed
2.Kirschstein, R. Disease-specific estimates of direct and indirect costs of illness and NIH support. Fiscal year 2000 update. National Institutes of Health. Available at http://ospp.od.nih.gov/ecostudies/COIreportweb.htm. Accessed September 25, 2006.Google Scholar
3.Mount, C, Downton, C. Alzheimer disease:  progress or profit? Nature Medicine. 2006;12:780784.CrossRefGoogle ScholarPubMed